LWM
ALNY icon

Lodestone Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lodestone Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5K Hold
5
– – ﹤0.01% 708
2026
Q1 		$1.65K Hold
5
– – ﹤0.01% 689
2025
Q4 		$1.99K Buy
+5
New +$2.21K ﹤0.01% 678

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lodestone Wealth Management's ALNY Position: Q2 2026 in Review

Lodestone Wealth Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 5 shares worth $1.5K. The position accounts for ﹤0.01% of the portfolio, ranked #708.

Lodestone Wealth Management first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.99K in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Lodestone Wealth Management held 5 shares of Alnylam Pharmaceuticals worth $1.5K as of Q2 2026.
  • Lodestone Wealth Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Lodestone Wealth Management's portfolio in Q2 2026, its #708 holding.
  • Lodestone Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Lodestone Wealth Management's Alnylam Pharmaceuticals position peaked at $1.99K in Q4 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Lodestone Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.